BioSpace Article – Published: Nov 22, 2023 By Nadia Bey From Ali Pashazadeh’s perspective, many trials fail because of how they are designed. And as the
NEW YORK, NY & LONDON – Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical-stage assets, further
The service has been developed to meet headwinds faced by the biotech sector, further exacerbated by a challenging financing and licensing environment London, UK, October
Syneos One and Treehill Partners discuss how Korean biotech companies can optimize for the realities of today, highlighting alternate pathways to global markets and critical
The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no
The game has changed in biotech. Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry,
Evaluate and Treehill Partners discuss the state of play and look for smart ways to get investment and deals moving as we head into 2023.
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.